Recent Years Show Booms for Oncotarget

The work just keeps rolling out due to the production of Oncotarget and its network of researchers. Over a span of just only 5 years, from 2011 to 2016, records show chart breaking numbers for citation in research submitted. This is most likely indicated of a rise in the standard in quality or a phenomenon that still remains unexplained. Numbers do not lie. They only try to explain the phenomenons that we see happening in our reality. And, in the case of Oncotarget, the reality base is long and wide ranged like the various subjects that are affected by oncology.

So, can these numbers really be explained in simple words without some type of facts or figures involved? Once you have laid eyes on the work product coming from the organization by Mikhail Blagosklonny, the answer becomes clear as a bell ringing on a sunny day. Yes. The fact finders on these projects are serious about their work product and nothing is ever overlooked. Things are perfect down to the 97 percentile. Some of these studies include subject matter that is not so complicated such as photodynamic therapy on some of fibrosis patients especially where Xeroderma pigmentosum and for Goblin Goltz syndrome.

Other studies show near miraculous results as in tumor suppression in the cases of metastasis.What this basically looks like is a spike from 4.8 citations for document to 8.4 over the course of 2011 to 2016. Not to mention that over the same course of time total citations for the organization as a whole jumped from 0 to 20,000 while self citations remained incredibly low points to the due diligence of the work submitted. Which coincides nicely with the international collaboration stats which went from 22.5 in 2011 to 37.5 by 2014 and just above 30 in 2016. The number of citable and cited documents climb steadily over the same course of time 2011-2016 from 0 to 5000 easily.